Dermavant Sciences, a biopharmaceutical company focused on delivering therapies for dermatologic conditions, has bolstered its executive team with the addition of four new hires.
David Rubenstein, GlaxoSmithKline’s former vice president, discovery and preclinical development, joins the group as its new chief scientific officer.
Prior to GSK, Rubenstein held academic roles at the University of North Carolina.
Alongside Rubenstein, Richard Peterson joins the biopharma as its chief financial officer.
Peterson, who previously worked at Sienna Biopharmaceuticals as its chief financial officer, comes to Dermavant Sciences with experience in the dermatology space.
He has previously served as chief financial officer for Novan and chief financial officer, executive vice president of Medicis Pharmaceutical Corporation.
Also joining the team is new chief business and strategy officer Ariel Jasie.
Jasie has joined the biopharma from Codiak BioSciences, where he served as chief business officer and prior to that, he served in various executive roles at Celgene, most recently as executive director for strategy and operations.
Completing the line-up of new additions is Chris Van Tuyl, who joins as general counsel.
He has previously served in numerous positions such as corporate secretary, chief compliance officer and associate general counsel at Rayonier, where he oversaw key aspects of the company’s spinoff of its chemical business in 2014.
Dr Jacqualyn Fouse, executive chair of Dermavant, said: “I am delighted to welcome David, Richard, Ariel and Chris to our team and we look forward to advancing the development of a promising treatment for hyperhidrosis.”